WuQiang Fan WuQiang Fan

Dr. WuQiang Fan WuQiang Fan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
WFWuQiang Fan WuQiang Fan
WuQiang Fan WuQiang Fan
MMMelissa Machado
Melissa Machado
BLBenjamin Z Leder
Benjamin Z Leder
LBLisa Beyer
Lisa Beyer
EGEsteban Franco Garcia
Esteban Franco Garcia
MBMarcy B Bolster
Marcy B Bolster
Context: Fragility fractures increase risks for future fractures, morbidity, and mortality. Available pharmacotherapy for underlying osteoporosis is safe and effective but underused. Objective: To improve pharmacotherapy rate representing secondary prevention of osteoporotic fractures. Methods: This single-center, observational, follow-up study included patients with fragility fractures admitted to the Massachusetts General Hospital between February 2016 and December 2019. For patients admitted to the orthopedics service with fragility fracture, the Massachusetts General Hospital Fracture Liaison Service (FLS) was systematically consulted. Initial outpatient follow-up with FLS was established in conjunction with the orthopedic postoperative follow-up visit. Patients at risk for failing timely outpatient follow-up were administered zoledronic acid (ZA) during the index fracture hospitalization. The main outcome measures were percentage of patients with fragility fracture(s) started on pharmacotherapy for osteoporosis and average length of stay and 30-day readmission rate of patients treated with ZA. Results: Compared with baseline (8-11%) and reference (5-20%) rates, integration of FLS to the orthopedics service, along with appropriate inpatient administration of ZA, increased the pharmacotherapy rate to 70% (412/589) among eligible patients with verified treatment status. Inpatient ZA administration neither affected the average length of stay nor 30-day readmission rate. Treatment status of 37.9% (471/1240) of the study patients remained unknown due to lack of or unknown follow-up. Conclusion: Integration of a FLS and orthopedics services along with inpatient ZA administration improved the osteoporosis pharmacotherapy rate among patients with fragility fracture(s) who often had obstacles for outpatient follow-up.

2 July 2024 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
PDF file
WFWuQiang Fan WuQiang Fan
WuQiang Fan WuQiang Fan
XSXiaoxu Sun
Xiaoxu Sun
BLBenjamin Z Leder
Benjamin Z Leder
HLHang Lee
Hang Lee
TLThuan V Ly
Thuan V Ly
MBMarcy B Bolster
Marcy B Bolster
Inpatient zoledronic acid (IP-ZA) administered during the initial fracture hospitalization significantly improves the osteoporosis treatment rate. Clinical outcomes of IP-ZA after hip fracture remains uncertain. Here we report a new-user active comparator cohort study that emulated a randomized controlled trial using real-world data and evaluated the risk of death of any cause and radiologically confirmed subsequent new fractures among patients hospitalized for a hip fracture who had received IP-ZA as compared with propensity-matched controls who were not treated with anti-osteoporosis medication within the first-year post fracture. 654 patients who had received IP-ZA and 6877 controls (for whom antiosteoporosis treatment was indicated but no IP-ZA started during index hospitalization) were included in the study. The primary cohort comprised 652 IP-ZA patients (IP-ZA group) and 1926 matched controls (Untreated group) with 71.7% female, 92.1% White, and mean age of 80.9 years. Cumulative all-cause-mortality over the 24 months follow-up for the IP-ZA group was 12.3%, and 20.7% for Untreated group [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.49-0.78, p < 0.001)]. 585 (89.7%) patients in IP-ZA group received only a single dose of ZA during the 24 months, and the death rate of this single dose group was 13.3%, which was significantly lower than that of the Untreated group (HR, 0.70; 95% CI, 0.55-0.89, p = 0.003). Rates of radiologically confirmed cumulative subsequent new vertebral fractures were 2.0% in IP-ZA group and 5.4% in Untreated group (HR, 0.40; 95% CI, 0.22-0.71, P = 0.001). A similarly lower rate of new vertebral fractures was seen in the single dose subgroup (1.9% vs. 5.4%. HR, 0.44; 95% 0.24-0.82, p = 0.008). IP-ZA, administered during the initial hospitalization for hip fracture, was associated with lower all-cause-mortality and risk of radiologically confirmed subsequent new vertebral fractures, and thus offers a mechanism to narrow the treatment gap in patients having sustained a hip fragility fracture. Hip fracture is a serious complication of osteoporosis affecting approximately 300 000 Americans per year and is associated with a 20-30% one-year mortality rate. Most patients with hip fracture are elderly (average age 80-81 years), with multiple underlying medical conditions and are often unable to timely attend post-hospitalization outpatient follow-up to initiate anti-osteoporosis treatment. As a result, only ~10% of post-hip fracture patients receive treatment for underlying osteoporosis. We have previously reported that zoledronic acid (ZA) administered during initial fracture hospitalization (IP-ZA) is safe and can effectively improve the osteoporosis treatment rate to 70%. The present study analyzed the clinical outcomes of 652 patients who had sustained hip fractures and were treated with IP-ZA and 1926 matched controls and revealed significantly reduced rates of all-cause mortality and vertebral compression fracture (VCF) during a 2-year follow-up period. Of note, nearly 90% of the treated patients received only a single dose of ZA (namely, IP-ZA), suggesting that, for most patients, the only opportunity to receive anti-osteoporosis treatment was during the index fracture hospitalization. Importantly, reduced mortality and VCF rates were readily seen in this single-dose group of patients. Our data suggests that IP-ZA is beneficial for osteoporotic hip fracture.

1 July 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
WFWuQiang Fan WuQiang Fan
WuQiang Fan WuQiang Fan
HZHui Zheng
Hui Zheng
NWNancy Wei
Nancy Wei
DNDavid M. Nathan
David M. Nathan

25 May 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
WFWuQiang Fan WuQiang Fan
WuQiang Fan WuQiang Fan
BLBenjamin Z Leder
Benjamin Z Leder
MMMichael Mannstadt
Michael Mannstadt
TLThuan V Ly
Thuan V Ly
EFEsteban Franco-Garcia
Esteban Franco-Garcia
MBMarcy B Bolster
Marcy B Bolster
Context Zoledronic acid (ZA) administered during the initial hospitalization for a fragility fracture improves the osteoporosis pharmacotherapy rate. Distinguishing the safety profile of inpatient ZA (IP-ZA) in this context is crucial if this approach is to be widely adopted. Objective To study the acute safety profile of IP-ZA. Design, Setting and Patients An observational study of patients admitted to the Massachusetts General Hospital with fragility fractures who were eligible to receive IP-ZA. Intervention Patients were treated with or without IP-ZA. Acetaminophen, either as a single pre-ZA dose or standing multiple-doses-per-day for 48 hours or longer after ZA infusion, was also administered along with protocolized vitamin D and calcium supplementation. Main outcome measures changes in body temperature, serum creatinine and serum calcium. Results 285 consecutive patients, meeting inclusion and exclusion criteria, are included in this analysis. 204 patients received IP-ZA. IP-ZA treatment was associated with a transient mean rise of body temperature of 0.31oC on the day following its administration. 15% of patients in the IP-ZA group and 4% in the non-treated group had temperatures above 38oC. Standing multiple-doses-per-day, but not a single pre-ZA dose of acetaminophen, effectively prevented this temperature increase. IP-ZA did not affect serum creatinine levels. Mean levels of serum total calcium and albumin-corrected calcium decreased by 0.54 mg/dl and 0.40 mg/dl, respectively, at their nadirs (Day 5). No patient experienced symptomatic hypocalcemia. Conclusions IP-ZA along with standing multiple-doses-per-day acetaminophen, administered to patients in the immediate post-fracture period, is not associated with significant acute adverse effects.

11 October 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
XSXiaoxu Sun
Xiaoxu Sun
MBMarcy B Bolster
Marcy B Bolster
BLBenjamin Z Leder
Benjamin Z Leder
WFWuQiang Fan WuQiang Fan
WuQiang Fan WuQiang Fan
Context Patients with osteoporosis and advanced chronic kidney disease (CKD) are at increased risk for hypocalcemia when initiating denosumab. It remains unclear if subsequent doses of denosumab pose similar hypocalcemia risk as the initial dose does. Objectives To study dose-specific hypocalcemia risks of denosumab. Design, Setting, Patients and Exposure An observational study of 10,398 consecutive patients with varying renal function who received denosumab within Mass General Brigham healthcare system between 1/1/2016 and 2/29/2024. Main Outcomes and Measures Dose-specific effects of denosumab on serum calcium levels and incidence of hypocalcemia (albumin-corrected serum calcium level < 8.5 mg/dl). Results In 159 patients with sufficient data for three consecutive doses of denosumab, the initial dose of denosumab reduced serum calcium levels by an average of 0.34, 0.52, and 1.12 mg/dl, in patients with GFR of ≥60 (n=89), 30-59 (n=46) and < 30 (n=24) ml/min/1.73m2, respectively (p<0.001). Among patients with GFR of < 30 ml/min/1.73m2, the initial, second, and third dose of denosumab reduced serum calcium levels by an average of 1.12, 0.72, and 0.60 mg/dl, respectively (p=0.014). In a cohort of 325 patients with sufficient data for two doses of denosumab, a Kaplan-Meier analysis revealed a trend of higher incidence of hypocalcemia following the initial dose compared to the second dose in patients with GFR of < 30 ml/min/1.73m2. Conclusions The magnitude of serum calcium decrease following subsequent dose(s) was smaller than that following the initial dose of denosumab among patients with osteoporosis and advanced CKD.

22 March 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
WFWuQiang Fan WuQiang Fan
WuQiang Fan WuQiang Fan
BLBenjamin Z Leder
Benjamin Z Leder
MBMarcy B Bolster
Marcy B Bolster
WuQiang Fan, Benjamin Z Leder, Marcy B Bolster; Response to Letter to the Editor from Riahi and Gruntmanis: ‘Inpatient Zoledronic Acid and Integrated Orthopedic